Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07548476 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy

Study acronym: ACE
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 4 months later Mar 2, 2027 → Aug 2028
Enrollment reduced 60% 50 → 20 participants
See other at-risk trials from Dana-Farber Cancer Institute

Record History

  1. Start date changed from estimate of Aug 2026 to Sep 3, 2026v4
  2. Primary and study completion pushed from Mar 2, 2027 to Aug 2028 Enrollment reduced: 50 → 20 participants · Recruitment opened · Start date: Oct 2, 2026 to Aug 2026 · 3 morev3 Show 6 more changesShow less
    • Enrollment reduced: 50 → 20 participants
    • Recruitment opened
    • Start date: Oct 2, 2026 to Aug 2026
    • Eligibility criteria expanded, about 110 words
    • Site details revised
    • Study description shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Eligibility criteria revisedv2 See this version in full on ClinicalTrials.gov ↗
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to evaluate the feasibility and preliminary efficacy of a combined acupuncture and exercise intervention for the management of chemotherapy-induced peripheral neuropathy (CIPN) in participants with bladder cancer receiving enfortumab vedotin (EV) and pembrolizumab (Pembro). The names of the two study groups in this research study are: * Acupuncture + Virtual Exercise (AVE) * Virtual Exercise Only (VE)
Trial Details
NCT Number NCT07548476
Lead Sponsor Dana-Farber Cancer Institute
Conditions Metastatic Bladder Cancer, Peripheral Neuropathy, Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Bladder Cancer, Urothelial Cancer
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov